Radium-223 Therapy for Patients with Metastatic Castrate-Resistant Prostate Cancer: An Update on Literature with Case Presentation

Figure 3

Case #3 of a 67-year-old man. Anterior and posterior bone scan, and CT at baseline (a, b, c) and within 3 months after completion of Radium-223 (d, e, f). Imaging findings are summarized in Table 3.

(a)

(b)

(c)

(d)

(e)

(f)